Gastrointestinal Cancer

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Fruquintinib increases overall survival in metastatic colorectal carcinoma

Biological agents that target VEGF or EGFR are often used in conjunction with other chemotherapies to treat metastatic colorectal carcinoma (CRC).

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

By

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

Aspirin and Colorectal Cancer

Aspirin and Colorectal Cancer

By

Studies attempting to link ASA to a reduction in the risk of CRC have had mixed results.

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in <I>BRAF<sup>V600E</sup></i>-Mutant CRC

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

By

Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Vitamin D and Colorectal Cancer

Vitamin D and Colorectal Cancer

By

The vitamin D response element plays a direct role in regulating gene expression, a potential mechanism to explain how vitamin D is involved with malignancy.

Colon Cancer Treatment Regimens

View a detailed drug treatment regimen for colon cancer, including therapies such as FOLFOX, FOLFIRI, and more.

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

By

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

FDA-Approved Colorectal Cancer Drug Treatments

Colorectal cancer treatment regimen chart.

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

By

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Colon Cancer Screening: American Cancer Society Guidelines Update

Colon Cancer Screening: American Cancer Society Guidelines Update

By

An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.

Real-World Study Reports PFS and OS in Metastatic CRC

Real-World Study Reports PFS and OS in Metastatic CRC

By

A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

By

Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

By

Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

By

CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

By

Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

By

A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

By

XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

By

In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

By

The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

By

The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

By

Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

By

A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs